New Mexico: Pfizer and BioNTech said on Tuesday that they had submitted data to U.S. regulators that the companies said showed that their coronavirus vaccine is safe and effective in children ages 5 to 11.
The companies said that they would submit a formal request to allow a pediatric dose of their vaccine to be administered in the U.S. in the coming weeks. Similar requests will be filed with European regulators and in other countries.
About a week ago, Pfizer and BioNTech announced favorable results from their clinical trial with more than 2,200 participants in that age group.
Context: About 28 million children ages 5 to 11 would be eligible for the vaccine in the U.S., far more than the 17 million of ages 12 to 15 who became eligible for the vaccine in May.